These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 22569124)

  • 1. A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge.
    Reynolds MR; Weiler AM; Piaskowski SM; Piatak M; Robertson HT; Allison DB; Bett AJ; Casimiro DR; Shiver JW; Wilson NA; Lifson JD; Koff WC; Watkins DI
    Vaccine; 2012 Jun; 30(30):4465-75. PubMed ID: 22569124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine.
    Qureshi H; Ma ZM; Huang Y; Hodge G; Thomas MA; DiPasquale J; DeSilva V; Fritts L; Bett AJ; Casimiro DR; Shiver JW; Robert-Guroff M; Robertson MN; McChesney MB; Gilbert PB; Miller CJ
    J Virol; 2012 Feb; 86(4):2239-50. PubMed ID: 22156519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination of Macaques with DNA Followed by Adenoviral Vectors Encoding Simian Immunodeficiency Virus (SIV) Gag Alone Delays Infection by Repeated Mucosal Challenge with SIV.
    Almond N; Berry N; Stebbings R; Preston M; Ham C; Page M; Ferguson D; Rose N; Li B; Mee ET; Hassall M; Stahl-Hennig C; Athanasopoulos T; Papagatsias T; Herath S; Benlahrech A; Dickson G; Meiser A; Patterson S
    J Virol; 2019 Nov; 93(21):. PubMed ID: 31413132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Frequency of Vaccine-Induced T-Cell Responses Does Not Predict the Rate of Acquisition after Repeated Intrarectal SIVmac239 Challenges in
    Martins MA; Gonzalez-Nieto L; Shin YC; Domingues A; Gutman MJ; Maxwell HS; Magnani DM; Ricciardi MJ; Pedreño-Lopez N; Bailey VK; Altman JD; Parks CL; Allison DB; Ejima K; Rakasz EG; Capuano S; Desrosiers RC; Lifson JD; Watkins DI
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541854
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Martins MA; Tully DC; Pedreño-Lopez N; von Bredow B; Pauthner MG; Shin YC; Yuan M; Lima NS; Bean DJ; Gonzalez-Nieto L; Domingues A; Gutman MJ; Maxwell HS; Magnani DM; Ricciardi MJ; Bailey VK; Altman JD; Burton DR; Ejima K; Allison DB; Evans DT; Rakasz EG; Parks CL; Bonaldo MC; Capuano S; Lifson JD; Desrosiers RC; Allen TM; Watkins DI
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29875239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge.
    Malherbe DC; Mendy J; Vang L; Barnette PT; Reed J; Lakhashe SK; Owuor J; Gach JS; Legasse AW; Axthelm MK; LaBranche CC; Montefiori D; Forthal DN; Park B; Wilson JM; McLinden JH; Xiang J; Stapleton JT; Sacha JB; Haynes BF; Liao HX; Ruprecht RM; Smith J; Gurwith M; Haigwood NL; Alexander J
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29093095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vector Order Determines Protection against Pathogenic Simian Immunodeficiency Virus Infection in a Triple-Component Vaccine by Balancing CD4
    Sauermann U; Radaelli A; Stolte-Leeb N; Raue K; Bissa M; Zanotto C; Krawczak M; Tenbusch M; Überla K; Keele BF; De Giuli Morghen C; Sopper S; Stahl-Hennig C
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28904195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine protection against simian immunodeficiency virus in monkeys using recombinant gamma-2 herpesvirus.
    Bilello JP; Manrique JM; Shin YC; Lauer W; Li W; Lifson JD; Mansfield KG; Johnson RP; Desrosiers RC
    J Virol; 2011 Dec; 85(23):12708-20. PubMed ID: 21900170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic T-lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus-boosted and DNA-primed Mamu-A*01-positive rhesus macaques.
    McDermott AB; O'Connor DH; Fuenger S; Piaskowski S; Martin S; Loffredo J; Reynolds M; Reed J; Furlott J; Jacoby T; Riek C; Dodds E; Krebs K; Davies ME; Schleif WA; Casimiro DR; Shiver JW; Watkins DI
    J Virol; 2005 Dec; 79(24):15556-66. PubMed ID: 16306626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological and virological analyses of rhesus macaques immunized with chimpanzee adenoviruses expressing the simian immunodeficiency virus Gag/Tat fusion protein and challenged intrarectally with repeated low doses of SIVmac.
    Cervasi B; Carnathan DG; Sheehan KM; Micci L; Paiardini M; Kurupati R; Tuyishime S; Zhou XY; Else JG; Ratcliffe SJ; Ertl HC; Silvestri G
    J Virol; 2013 Sep; 87(17):9420-30. PubMed ID: 23804645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques.
    Malkevitch N; Patterson LJ; Aldrich K; Richardson E; Alvord WG; Robert-Guroff M
    J Immunol; 2003 Apr; 170(8):4281-9. PubMed ID: 12682263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model.
    Suh YS; Park KS; Sauermann U; Franz M; Norley S; Wilfingseder D; Stoiber H; Fagrouch Z; Heeney J; Hunsmann G; Stahl-Hennig C; Sung YC
    Vaccine; 2006 Mar; 24(11):1811-20. PubMed ID: 16274888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with Gag, Vif, and Nef gene fragments affords partial control of viral replication after mucosal challenge with SIVmac239.
    Martins MA; Wilson NA; Piaskowski SM; Weisgrau KL; Furlott JR; Bonaldo MC; Veloso de Santana MG; Rudersdorf RA; Rakasz EG; Keating KD; Chiuchiolo MJ; Piatak M; Allison DB; Parks CL; Galler R; Lifson JD; Watkins DI
    J Virol; 2014 Jul; 88(13):7493-516. PubMed ID: 24741098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses.
    Malkevitch NV; Patterson LJ; Aldrich MK; Wu Y; Venzon D; Florese RH; Kalyanaraman VS; Pal R; Lee EM; Zhao J; Cristillo A; Robert-Guroff M
    Virology; 2006 Sep; 353(1):83-98. PubMed ID: 16814356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD8 T Cells Show Protection against Highly Pathogenic Simian Immunodeficiency Virus (SIV) after Vaccination with SIV Gene-Expressing BCG Prime and Vaccinia Virus/Sendai Virus Vector Boosts.
    Kato S; Shida H; Okamura T; Zhang X; Miura T; Mukai T; Inoue M; Shu T; Naruse TK; Kimura A; Yasutomi Y; Matsuo K
    J Virol; 2021 Jan; 95(4):. PubMed ID: 33087465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.
    Pal R; Venzon D; Letvin NL; Santra S; Montefiori DC; Miller NR; Tryniszewska E; Lewis MG; VanCott TC; Hirsch V; Woodward R; Gibson A; Grace M; Dobratz E; Markham PD; Hel Z; Nacsa J; Klein M; Tartaglia J; Franchini G
    J Virol; 2002 Jan; 76(1):292-302. PubMed ID: 11739694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged survival of vaccinated macaques after oral SIVmac239 challenge regardless of viremia control in the chronic phase.
    Suh YS; Park KS; Sauermann U; Kim KS; Ahn SS; Franz M; Schulte R; Wilfingseder D; Stoiber H; Uberla K; Hunsmann G; Stahl-Hennig C; Sung YC
    Vaccine; 2008 Dec; 26(51):6690-8. PubMed ID: 18694796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses.
    Hel Z; Nacsa J; Tryniszewska E; Tsai WP; Parks RW; Montefiori DC; Felber BK; Tartaglia J; Pavlakis GN; Franchini G
    J Immunol; 2002 Nov; 169(9):4778-87. PubMed ID: 12391187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gag-specific cellular immunity determines in vitro viral inhibition and in vivo virologic control following simian immunodeficiency virus challenges of vaccinated rhesus monkeys.
    Stephenson KE; Li H; Walker BD; Michael NL; Barouch DH
    J Virol; 2012 Sep; 86(18):9583-9. PubMed ID: 22761379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge.
    Seth A; Ourmanov I; Schmitz JE; Kuroda MJ; Lifton MA; Nickerson CE; Wyatt L; Carroll M; Moss B; Venzon D; Letvin NL; Hirsch VM
    J Virol; 2000 Mar; 74(6):2502-9. PubMed ID: 10684264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.